DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm count
Six months of hydroxyurea therapy detrimentally effected spermatogenesis in men with sickle cell anemia, according to a small prospective study published in Blood.
“Hydroxyurea, at current doses, causes significant, rapid and unpredictable impairment of spermatogenesis in treated men,” Isabelle Berthaut, PhD, professor of histology and biology of reproduction at Tenon Hospital in Paris, and colleagues wrote.
Hydroxyurea — approved by the FDA in 1998 for the treatment of sickle cell anemia — helps reduce the production of sickle hemoglobin. Its side effects include low blood counts, gastrointestinal symptoms and loss of appetite.
Three previous retrospective studies showed an association between hydroxyurea and potentially detrimental effects on sperm parameters in men with sickle cell anemia. However, those observations occurred on studies involving as few as eight men, seven of whom did not have any comparative semen assessment prior to hydroxyurea initiation.
Related Content
-
education & researchHydroxyurea Treatment for Sickle Cell Disease – Children’s National Health SystemAt Children’s National, we understand ...
-
education & researchEffects of Hydroxyurea (HU) on Neurocognitive Performance in Children With Sickle Cell Disease: A Prospective TrialSickle cell anemia is associated with pr...
-
news & eventsSickle Cell Disease Research Shows Progress in Preventing Related Complications and DeathStudies aim to limit pain crises, preven...
-
videos & visualsIs Your Child the Right Candidate for Hydroxyureahttps://www.youtube.com/watch?v=vMvC5rVH...
-
news & eventsEffort set to help sickle cell patients manage medsVanderbilt University Medical Center is ...
-
news & eventsSiklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
news & eventsSickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.